Liminatus Pharma Stock Price, News & Analysis
Company Description
Liminatus Pharma (NASDAQ: LIMNW) is a publicly traded company in the Biological Products, (no Diagnostic Substances) sector.
LIMNW stock has gained 28.6% over the past year. Shares last traded at $0.0775.
On a trailing twelve-month basis, Liminatus Pharma and diluted earnings per share of $-0.43.
This page provides a comprehensive overview of LIMNW stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Liminatus Pharma (LIMNW) stock last traded at $0.0775, up 54.84% from the previous close. Over the past 12 months, the stock has gained 28.6%.
Latest News
SEC Filings
Liminatus Pharma has filed 10 recent SEC filings, including 4 Form 8-K, 2 Form 10-Q, 2 Form 10-K, 2 Form SCHEDULE 13G. The most recent filing was submitted on May 20, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LIMNW SEC filings →
Financial Highlights
Diluted earnings per share stood at $-0.43. With a current ratio of 0.05, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Liminatus Pharma (LIMNW) currently stands at 158 shares, down 35.8% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 94%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Liminatus Pharma (LIMNW) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 1.6 days.
LIMNW Company Profile & Sector Positioning
Liminatus Pharma (LIMNW) operates in the Biological Products, (no Diagnostic Substances) sector and is listed on the NASDAQ.